Tenet Healthcare

THC

Market cap $20.3B

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Tenet (THC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

THC tops Q4 estimates with strong EBITDA growth, but 2026 guidance midpoint hints at a potential margin dip despite a higher revenue outlook.

Tenet Healthcare Corporation delivered a strong Q4 2025, beating revenue and EPS estimates, and provided favorable 2026 guidance. THC's Ambulatory Care segment drove growth, with a 13.8% revenue increase and robust EBITDA, despite a slight margin decline. The announced $1.9B transaction with CommonSpirit introduces uncertainty but will reduce net debt and grant full ownership of Conifer.

Tenet Healthcare Corporation (THC) Q4 2025 Earnings Call Transcript

Tenet Healthcare Corporation (NYSE: THC) reported fourth-quarter sales of $5.527 billion, up around 8.9% year over year.

The headline numbers for Tenet (THC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Tenet Healthcare (THC) came out with quarterly earnings of $4.7 per share, beating the Zacks Consensus Estimate of $4.08 per share. This compares to earnings of $3.44 per share a year ago.

DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended December 31, 2025. "2025 extended Tenet's track record of strong revenue growth, disciplined operations, improved margins and robust free cash flow generation," said Saum Sutaria, M.D., Chairman and Chief Executive Officer of Tenet. "We see continued demand for acute care and ambulatory surgical services in our markets and are confident in our ability to execute on our str.

THC heads into Q4 earnings with solid expected revenue and admissions growth, but a sharp drop in hospital patient days could cloud the bottom-line outlook.